FDA Approved Humalog KwikPen® for Type 1 & 2 Diabetes (粮食与药物管理局批准Humalog KwikPen® 治疗糖尿病)
In May 2015, The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s Humalog U-200 KwikPen (insulin lispro 200 units/mL; U-200) for people with type 1 and type 2 diabetes. It is a prefilled insulin pen containing a double strength formulation of the rapid acting insulin Humalog – This offers patients a pen that lasts longer between pen changes, allowing for fewer changes every month.
According to David Kendall, M.D., Vice President of Medical Affairs, at Lilly Diabetes. "Humalog U-200 KwikPen represents a new option for people with diabetes. Fewer pen changes per month may help people who require higher daily doses of mealtime insulin better fit their treatment in their daily lives."
The approval of Humalog U-200 KwikPen was based on a demonstration of the bioequivalence of Humalog 200 units/mL relative to Humalog 100 units/mL in a pharmacokinetic / pharmacodynamic study. The most common side effect of Humalog is Hypoglycemia (low blood sugar) that may be severe and cause unconsciousness, seizures and death. See my post on Hypoglycemia.
Once opened, Humalog prefilled pens should be thrown away after 28 days, even if insulin remains.
Humalog U-200 KwikPen was approved in the European Union since October 2014.
The Humalog U-200 KwikPen is expected to hit the shelves of U.S. pharmacies in August 2015.
For more information about the Humalog U200 KwikPen, click here for Full Prescribing Information from Eli Lilly.
My other Relevant Posts for your Reading (您能读其他相关的博克):
Disclaimer: I am not a Medical Doctor. All my blog postings are based on my personal experience that I've went thru and what I've read up from the internet. If you've any symptoms of diabetes OR want to better manage your health, I strongly urge you to have regular medical-ups to avoid future complications. In addition, control your diet portions and have regular exercise.